About
Oligomerix is a clinical-stage biotechnology company developing oral small molecule therapeutics that inhibit tau protein self-association to treat Alzheimer's disease and rare neurodegenerative tauopathies such as progressive supranuclear palsy.
Explore Oligomerix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.